Reduction of pain via platelet-rich plasma in splitthickness skin graft donor sites: A series of matched pairs

John D. Miller, Timothy M. Rankin, Natalie T. Hua, Tina Ontiveros, Nicholas A. Giovinco, Joseph L Mills, David G Armstrong

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the past decade, autologous platelet-rich plasma (PRP) therapy has seen increasingly widespread integration into medical specialties. PRP application is known to accelerate wound epithelialization rates, and may also reduce postoperative wound site pain. Recently, we observed an increase in patient satisfaction following PRP gel (Angel, Cytomedix, Rockville, MD) application to split-thickness skin graft (STSG) donor sites. We assessed all patients known to our university-based hospital service who underwent multiple STSGs up to the year 2014, with at least one treated with topical PRP. Based on these criteria, five patients aged 48.±17.6 (80% male) were identified who could serve as their own control, with mean time of 4.4 ± 5.1 years between operations. In both therapies, initial dressing changes occurred on postoperative day (POD) 7, with donor site pain measured by Likert visual pain scale. Paired t-tests compared the size and thickness of harvested skin graft and patient pain level, and STSG thickness and surface area were comparable between control and PRP interventions (p>0.05 for all). Donor site pain was reduced from an average of 7.2 (±2.6) to 3 (±3.7), an average reduction in pain of 4.2 (standard error 1.1, p=0.0098) following PRP use. Based on these results, the authors suggest PRP as a beneficial adjunct for reducing donor site pain following STSG harvest

Original languageEnglish (US)
JournalDiabetic Foot and Ankle
Volume6
DOIs
StatePublished - Jan 22 2015

Fingerprint

Platelet-Rich Plasma
Tissue Donors
Transplants
Pain
Skin
Re-Epithelialization
Bandages
Patient Satisfaction
Gels
Medicine
Wounds and Injuries
Therapeutics

Keywords

  • Diabetic foot
  • Pain reduction
  • Platelet-rich plasma
  • Skin grafts

ASJC Scopus subject areas

  • Podiatry
  • Internal Medicine

Cite this

Reduction of pain via platelet-rich plasma in splitthickness skin graft donor sites : A series of matched pairs. / Miller, John D.; Rankin, Timothy M.; Hua, Natalie T.; Ontiveros, Tina; Giovinco, Nicholas A.; Mills, Joseph L; Armstrong, David G.

In: Diabetic Foot and Ankle, Vol. 6, 22.01.2015.

Research output: Contribution to journalArticle

Miller, John D. ; Rankin, Timothy M. ; Hua, Natalie T. ; Ontiveros, Tina ; Giovinco, Nicholas A. ; Mills, Joseph L ; Armstrong, David G. / Reduction of pain via platelet-rich plasma in splitthickness skin graft donor sites : A series of matched pairs. In: Diabetic Foot and Ankle. 2015 ; Vol. 6.
@article{f2ca131837804b248e38925d6b342a8e,
title = "Reduction of pain via platelet-rich plasma in splitthickness skin graft donor sites: A series of matched pairs",
abstract = "In the past decade, autologous platelet-rich plasma (PRP) therapy has seen increasingly widespread integration into medical specialties. PRP application is known to accelerate wound epithelialization rates, and may also reduce postoperative wound site pain. Recently, we observed an increase in patient satisfaction following PRP gel (Angel, Cytomedix, Rockville, MD) application to split-thickness skin graft (STSG) donor sites. We assessed all patients known to our university-based hospital service who underwent multiple STSGs up to the year 2014, with at least one treated with topical PRP. Based on these criteria, five patients aged 48.±17.6 (80{\%} male) were identified who could serve as their own control, with mean time of 4.4 ± 5.1 years between operations. In both therapies, initial dressing changes occurred on postoperative day (POD) 7, with donor site pain measured by Likert visual pain scale. Paired t-tests compared the size and thickness of harvested skin graft and patient pain level, and STSG thickness and surface area were comparable between control and PRP interventions (p>0.05 for all). Donor site pain was reduced from an average of 7.2 (±2.6) to 3 (±3.7), an average reduction in pain of 4.2 (standard error 1.1, p=0.0098) following PRP use. Based on these results, the authors suggest PRP as a beneficial adjunct for reducing donor site pain following STSG harvest",
keywords = "Diabetic foot, Pain reduction, Platelet-rich plasma, Skin grafts",
author = "Miller, {John D.} and Rankin, {Timothy M.} and Hua, {Natalie T.} and Tina Ontiveros and Giovinco, {Nicholas A.} and Mills, {Joseph L} and Armstrong, {David G}",
year = "2015",
month = "1",
day = "22",
doi = "10.3402/dfa.v6.24972",
language = "English (US)",
volume = "6",
journal = "Diabetic Foot and Ankle",
issn = "2000-625X",
publisher = "Co-Action Publishing",

}

TY - JOUR

T1 - Reduction of pain via platelet-rich plasma in splitthickness skin graft donor sites

T2 - A series of matched pairs

AU - Miller, John D.

AU - Rankin, Timothy M.

AU - Hua, Natalie T.

AU - Ontiveros, Tina

AU - Giovinco, Nicholas A.

AU - Mills, Joseph L

AU - Armstrong, David G

PY - 2015/1/22

Y1 - 2015/1/22

N2 - In the past decade, autologous platelet-rich plasma (PRP) therapy has seen increasingly widespread integration into medical specialties. PRP application is known to accelerate wound epithelialization rates, and may also reduce postoperative wound site pain. Recently, we observed an increase in patient satisfaction following PRP gel (Angel, Cytomedix, Rockville, MD) application to split-thickness skin graft (STSG) donor sites. We assessed all patients known to our university-based hospital service who underwent multiple STSGs up to the year 2014, with at least one treated with topical PRP. Based on these criteria, five patients aged 48.±17.6 (80% male) were identified who could serve as their own control, with mean time of 4.4 ± 5.1 years between operations. In both therapies, initial dressing changes occurred on postoperative day (POD) 7, with donor site pain measured by Likert visual pain scale. Paired t-tests compared the size and thickness of harvested skin graft and patient pain level, and STSG thickness and surface area were comparable between control and PRP interventions (p>0.05 for all). Donor site pain was reduced from an average of 7.2 (±2.6) to 3 (±3.7), an average reduction in pain of 4.2 (standard error 1.1, p=0.0098) following PRP use. Based on these results, the authors suggest PRP as a beneficial adjunct for reducing donor site pain following STSG harvest

AB - In the past decade, autologous platelet-rich plasma (PRP) therapy has seen increasingly widespread integration into medical specialties. PRP application is known to accelerate wound epithelialization rates, and may also reduce postoperative wound site pain. Recently, we observed an increase in patient satisfaction following PRP gel (Angel, Cytomedix, Rockville, MD) application to split-thickness skin graft (STSG) donor sites. We assessed all patients known to our university-based hospital service who underwent multiple STSGs up to the year 2014, with at least one treated with topical PRP. Based on these criteria, five patients aged 48.±17.6 (80% male) were identified who could serve as their own control, with mean time of 4.4 ± 5.1 years between operations. In both therapies, initial dressing changes occurred on postoperative day (POD) 7, with donor site pain measured by Likert visual pain scale. Paired t-tests compared the size and thickness of harvested skin graft and patient pain level, and STSG thickness and surface area were comparable between control and PRP interventions (p>0.05 for all). Donor site pain was reduced from an average of 7.2 (±2.6) to 3 (±3.7), an average reduction in pain of 4.2 (standard error 1.1, p=0.0098) following PRP use. Based on these results, the authors suggest PRP as a beneficial adjunct for reducing donor site pain following STSG harvest

KW - Diabetic foot

KW - Pain reduction

KW - Platelet-rich plasma

KW - Skin grafts

UR - http://www.scopus.com/inward/record.url?scp=84929053894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929053894&partnerID=8YFLogxK

U2 - 10.3402/dfa.v6.24972

DO - 10.3402/dfa.v6.24972

M3 - Article

AN - SCOPUS:84929053894

VL - 6

JO - Diabetic Foot and Ankle

JF - Diabetic Foot and Ankle

SN - 2000-625X

ER -